Non-invasive eye exam found to predict disease severity in Friedreich’s ataxia

A study has found that a rapid, non-invasive eye exam could potentially be used as a tool for assessing Friedreich's ataxia patients and as a biomarker in clinical trials.Read more

Increasing levels of a protein in FA may be potential future therapy

Experiments performed in mice and in cells taken from Friedreich's ataxia (FA) patients reveal a protein called 'GRP75' might be an effective future treatment approach.Read more

Results presented from patient communications survey

The results of the patient communications survey conducted at the 2018 Ataxia UK conference were presented in London by Ataxia UK partners Costello Medical.Read more

HIV treatment identified as potential future therapy for FA

Study finds anti-viral drug leads to decrease in frataxin levels and may be a potential future candidate for treating Friedreich's ataxia (FA).Read more

SCA drug trial to begin in America

Second trial investigating troriluzole in spinocerebellar ataxia announced by Biohaven pharmaceuticals to commence at the end of January.Read more

Study discovers 3 potential blood based biomarkers for FA

Results from a study conducted at the London Ataxia Centre have shown that 3 proteins which may represent new biomarkers in Friedreich's ataxia (FA).Read more

Glut 1 deficiency syndrome trial announces negative results

A potential therapy for Glucose transporter 1 deficiency syndrome (Glut1 DS) has produced negative results in phase 3 of its clinical trial.Read more

Results published from part 1 of Friedreich's ataxia drug trial

Results from MOXIe study reveal potential therapy for Friedreich's ataxia, omaveloxolone, is well tolerated.Read more

International Ataxia Research Conference (IARC) 2019 - Save the date!

Ataxia UK, GoFAR, FARA US and FARA Australia are pleased to announce the date of 3rd International Ataxia Research Conference.Read more

Science and research funds from EU programmes guaranteed even in no-deal Brexit scenario

UK researchers guaranteed funding until the end of 2020 from EU programmes even in the event of a no-deal Brexit.Read more

Final draft of National Genomic Test Directory includes hereditary ataxia

NHS England has included hereditary ataxia in the final draft of the National Genomic Test Directory for rare and inherited disorders and cancerRead more

Investigational therapy, EPI-743, shows promise in Phase 2 clinical trial for Friedreich’s ataxia

Results from a phase 2 clinical trial suggest that a new therapy may improve neurological function and prevent disease progression relative to the natural course of Friedreich’s ataxia (FA).Read more

Interview with PhD student and ataxia researcher Wayne Yau

We interview PhD student Wayne Yau about life as an ataxia researcher working on an Ataxia UK funded investigation on the role of genetic DNA repair mechanisms in a range of ataxias.Read more

New EU Orphan drug designation for Freidreich’s ataxia

Omaveloxolone has recently been given an Orphan drug designation for Friedreich's ataxia the European Medicines Agency.Read more

New Friedreich’s ataxia trial started in America

A new placebo-controlled trail in humans, testing a novel therapy, Tak-831 for Friedreich's ataxia, has begun in America.Read more

Hope for gene therapy for Friedreich’s ataxia

This week results were published showing the effects of an AAV (adeno-associated virus) gene therapy in a new mouse model of Friedreich’s ataxia (FA).Read more

FDA oprphan drug designation for spinocerebellar ataxia

Biopharmaceutical company, IntraBio, has received an Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead compound (IB1000) for the treatment of spinocerebellar ataxias (SCA).Read more

AMRC releases annual research expenditure statistics

The AMRC has released their expenditure statistics for 2018.Read more

World Orphan Drug Congress 2018 – Washington DC

Ataxia UK was represented by research officer Dr Julie Vallortigara at the World Orphan Drug Congress in Washington DC. She shares her experience about this event.Read more

Raising awareness and understanding of ataxia among healthcare professionals

Ataxia UK attended conferences in Birmingham and St Asaph to and give talks about ataxia to health and social care professionals.Read more